USA's Digital Health TEMPO Trap: A Pure Global Critical Update

In this episode of MedTech Global Insights, we dissect two monumental shifts in the U.S. regulatory landscape happening right now. The FDA is rolling out its new TEMPO pilot program, offering a potential "regulatory light" pathway for digital health technologies. This could revolutionize market access for AI, machine learning, and chronic disease management devices. However, this opportunity is on a collision course with a major compliance deadline. In just a few weeks, the new, stricter Quality Management System Regulation (QMSR) becomes mandatory. We explore how companies can strategically leverage the promise of TEMPO without getting caught in the compliance trap of the QMSR, using recent successes from companies like Ceribell as a guide. Key Takeaways for this Episode: - What is the FDA's new TEMPO pilot, and could it be your ticket to the US market? - Why is the "regulatory light" approach for digital health not as simple as it sounds? - How can a platform technology strategy maximize the benefits of new FDA programs? - With the QMSR deadline weeks away, is your quality system truly inspection-ready? - How do you balance chasing new regulatory pathways while maintaining core compliance? - What are the critical documents you need prepared before applying to a program like TEMPO? - Could your supplier quality agreements put you at risk under the new QMSR? For more information, contact us at [email protected] or visit https://pureglobal.com/. You can also access our FREE AI tools and medical device database at https://pureglobal.ai/.